187 related articles for article (PubMed ID: 37658423)
1. Composite endpoints, including patient reported outcomes, in rare diseases.
Verbeeck J; Dirani M; Bauer JW; Hilgers RD; Molenberghs G; Nabbout R
Orphanet J Rare Dis; 2023 Sep; 18(1):262. PubMed ID: 37658423
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
4. Generalized Pairwise Comparisons to Assess Treatment Effects: JACC Review Topic of the Week.
Verbeeck J; De Backer M; Verwerft J; Salvaggio S; Valgimigli M; Vranckx P; Buyse M; Brunner E
J Am Coll Cardiol; 2023 Sep; 82(13):1360-1372. PubMed ID: 37730293
[TBL] [Abstract][Full Text] [Related]
5. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).
Brettschneider C; Lühmann D; Raspe H
GMS Health Technol Assess; 2011 Feb; 7():Doc01. PubMed ID: 21468289
[TBL] [Abstract][Full Text] [Related]
6. Improving the analysis of composite endpoints in rare disease trials.
McMenamin M; Berglind A; Wason JMS
Orphanet J Rare Dis; 2018 May; 13(1):81. PubMed ID: 29788976
[TBL] [Abstract][Full Text] [Related]
7. The art and science of choosing efficacy endpoints for rare disease clinical trials.
Cox GF
Am J Med Genet A; 2018 Apr; 176(4):759-772. PubMed ID: 29423972
[TBL] [Abstract][Full Text] [Related]
8. Statistical recommendations for count, binary, and ordinal data in rare disease cross-over trials.
Geroldinger M; Verbeeck J; Hooker AC; Thiel KE; Molenberghs G; Nyberg J; Bauer J; Laimer M; Wally V; Bathke AC; Zimmermann G
Orphanet J Rare Dis; 2023 Dec; 18(1):391. PubMed ID: 38115074
[TBL] [Abstract][Full Text] [Related]
9. Generalized pairwise comparison methods to analyze (non)prioritized composite endpoints.
Verbeeck J; Spitzer E; de Vries T; van Es GA; Anderson WN; Van Mieghem NM; Leon MB; Molenberghs G; Tijssen J
Stat Med; 2019 Dec; 38(30):5641-5656. PubMed ID: 31659790
[TBL] [Abstract][Full Text] [Related]
10. Systematic review of outcomes and endpoints in acute migraine clinical trials.
Houts CR; McGinley JS; Nishida TK; Buse DC; Wirth RJ; Dodick DW; Goadsby PJ; Lipton RB
Headache; 2021 Feb; 61(2):263-275. PubMed ID: 33611818
[TBL] [Abstract][Full Text] [Related]
11. Patient-Reported Outcome and Observer-Reported Outcome Assessment in Rare Disease Clinical Trials: An ISPOR COA Emerging Good Practices Task Force Report.
Benjamin K; Vernon MK; Patrick DL; Perfetto E; Nestler-Parr S; Burke L
Value Health; 2017; 20(7):838-855. PubMed ID: 28712612
[TBL] [Abstract][Full Text] [Related]
12. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
13. How to analyze continuous and discrete repeated measures in small-sample cross-over trials?
Verbeeck J; Geroldinger M; Thiel K; Hooker AC; Ueckert S; Karlsson M; Bathke AC; Bauer JW; Molenberghs G; Zimmermann G
Biometrics; 2023 Dec; 79(4):3998-4011. PubMed ID: 37587671
[TBL] [Abstract][Full Text] [Related]
14. Consistency-ensured parametric tests for critical events of composite endpoints.
Huque MF; Alosh M; Guerra M
J Biopharm Stat; 2018; 28(1):82-98. PubMed ID: 29144871
[TBL] [Abstract][Full Text] [Related]
15. Performance of Crohn's disease Clinical Trial Endpoints based upon Different Cutoffs for Patient Reported Outcomes or Endoscopic Activity: Analysis of EXTEND Data.
Feagan B; Sandborn WJ; Rutgeerts P; Levesque BG; Khanna R; Huang B; Zhou Q; Maa JF; Wallace K; Lacerda A; Thakkar RB; Robinson AM
Inflamm Bowel Dis; 2018 Apr; 24(5):932-942. PubMed ID: 29668919
[TBL] [Abstract][Full Text] [Related]
16. Mapping clinical outcomes to generic preference-based outcome measures: development and comparison of methods.
Hernández Alava M; Wailoo A; Pudney S; Gray L; Manca A
Health Technol Assess; 2020 Jun; 24(34):1-68. PubMed ID: 32613941
[TBL] [Abstract][Full Text] [Related]
17. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
18. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
